Adis Journals
Browse

Implementation of Empagliflozin in Patients With Diabetes Mellitus Type 2 and Established Cardiovascular Disease – Estimation of Five-Year Survival and Costs in Sweden

Download (72.1 kB)
media
posted on 2020-10-05, 11:49 authored by Lars Bernfort, Magnus Husberg, Ann-Britt Wiréhn, Ulf Rosenqvist, Staffan Gustavsson, Kristina Karlsdotter, Lars-Åke Levin
<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p>

History

Related Materials

  1. 1.
    URL - References https://link.springer.com/article/10.1007/s13300-020-00937-4
  2. 2.
    DOI - Is supplement to Implementation of Empagliflozin in Patients With Diabetes Mellitus Type 2 and Established Cardiovascular Disease – Estimation of Five-Year Survival and Costs in Sweden

Usage metrics

    Diabetes Therapy

    Categories

    Keywords

    Cardiovascular diseaseDisease burdenHealthcare costsMortalityPharmaceutical treatmentRegister studySGLT-2 inhibitorsType 2 diabetes

    Licence

    CC BY-NC 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC